Dr. Abdul Aziz Al-Malik has been the executive director of the Life Sciences and Environment Research Institute (LSERI) at King Abdul Aziz City for Science and Technology (KACST) since January 2015.
He established and headed the nanomedicine research group at the institute before being appointed deputy director for scientific affairs.
Al-Malik is also an assistant research professor of nanomedicine at KACST and an adjunct assistant professor of pharmaceutical biotechnology at the pharmacy school of King Saud University in Riyadh.
In addition, he has been chairman of the joint board between KACST and Brigham and Women’s Hospital at the Harvard Center of Excellence for Biomedicine-CEBM since May 2017.
In 2013, Al-Malik gained a Ph.D. in pharmaceutical sciences from The University of Manchester, in the UK. During the same year, he was awarded by the Saudi ambassador to the UK for his scientific distinction.
He received a master’s degree with merit in clinical pharmacology from the University of Glasgow, in Scotland, in 2008.
KACST and the National Center for Disease Prevention and Control (CDC) on Monday launched a platform to monitor antibiotic-resistant germs in government and private health facilities throughout Saudi Arabia.
Al-Malik said the initiative was the result of a successful partnership between the research and development program of infectious diseases and the program of antibiotic-resistant germs at the CDC.
